Albert Huang

Managing Director at Yunfeng Capital

Speaker

Dr. Albert Huang serves as Managing Director of Yunfeng Capital, Secretary-General of Tsinghua Yangtze River Delta Biomedical Alumni Association, as well as Board Member of Cellular Biomedicine Group (CBMG), MicroPort Sorin CRM (Shanghai) Co. Ltd., Sironax, Wuxi Diagnostics, Hailai Xinchuang, Yao123.com and American-Sino Women's and Children's Hospital.

He leads the development and implementation of projects in various industries such as biomedicine, diagnosis, medical devices, and genetic data, and has accumulated more than ten years of experience in research and development, management and investment in the medical and health sector, including investing in small nucleic acid innovative pharmaceutical companies Brii Biosciences (Brii Bio, HK.2137), mRNA vaccine drug company Suzhou Abogen Biosciences, electric field therapy Hailai Xinchuang, acquisition of Sorin, a global top 5 cardiac pacemaker company, investment in WuXi AppTech (SH.603259) privatization and Tigermed (HK.3347), and acquisition, management and successful exit of ReLIA, a US in vitro diagnostic company.

Albert received his Ph.D. in Biologic and Biomedical Sciences from Yale University and Bachelor in Biomedical Sciences from Tsinghua University. He worked as a project manager in the medical and healthcare group of Boston Consulting Group. Albert was named as one of the "36 Under 36" investors by 36Kr and the "40 Under 40" investors by Cyzone. He is a member and keynote speaker of the National Health Commission's Medical Science and Technology Achievement Transformation Evaluation Committee, as well as a consultant on biomedical economics for multiple provinces and cities.